Harmony Biosciences Holdings (HRMY) EBT (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of EBT data on file, last reported at $39.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 30.59% year-over-year to $39.7 million; the trailing twelve-month figure through Mar 2026 stood at $197.6 million (changed 0.19% YoY), and the FY2025 full-year result was $215.1 million, up 12.13% from the prior year.
• EBT retreated to $39.7 million in Q1 2026, from $40.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $67.5 million in Q3 2025 to a low of $8.0 million in Q3 2022.
• A 5-year average of $42.6 million and a median of $44.1 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT surged 550.58% in 2023 and tumbled 50.8% in 2024, its largest moves.
• Tracing HRMY's EBT over 5 years: stood at $44.1 million in 2022, then dropped by 10.01% to $39.7 million in 2023, then jumped by 41.49% to $56.2 million in 2024, then dropped by 27.42% to $40.8 million in 2025, then dropped by 2.63% to $39.7 million in 2026.
• Business Quant data shows HRMY's EBT at $39.7 million in Q1 2026, $40.8 million in Q4 2025, and $67.5 million in Q3 2025.